Pharmaceutical distributor selects IBS software

Send to friend

INFORMATION: Free information is available from IBS on the subject in this story. Click here to request a copy

IBS, International Business Systems, has signed an agreement with Azienda Speciale Farmacie Comunali Riunite, an Italian pharmaceutical distributor, situated in Reggio Emilia, with a long history in the pharmaceutical distribution market.

Farmacie Comunali Riunite (FCR) has two warehouses and owns 24 pharmacies. The company distributes over 20,000 items and has annual revenue of EUR 140 million. FCR's business covers different various sectors including public administration, hospitals and homeopathy through B2B and B2C channels.

Farmacie Comunali Riunite was looking for a fully integrated SCM system to meet the fast-changing requirements of the pharmaceutical market. An accurate software selection led the company to choose IBS Pharma - a pharmaceutical SCM software - for its versatility and ability to fulfill specific market needs.

"Farmacie Comunali Riunite's decision to implement IBS Pharma bares witness to the high-value of our SCM software for the pharmaceutical distribution market," says Luca Cavenaghi, Pharma Business Manager at IBS Italy. "The complete set of features combined with the integrated modules in a unique platform. The technological innovation of the SCM system is the main driver that convinced the customer to adopt our solution."

"Besides a pharmaceutical market-oriented system, we were looking for a reliable IT partner to support us in the delicate transition phase from our old SCM system to the new one," explains Mr Campari, General Manager of Farmacie Comunali Riunite. "The features of IBS Pharma combined with the skills and experience of IBS both in local and international projects represented the best assurance for the project success."

 

About IBS

IBS, (XSSE: IBS B) is a world leading provider of supply chain management solutions for distribution, demand-driven manufacturing, financials and business intelligence with group revenue of EUR 256 m. IBS primary focus is large and mid-sized distributors as well as sales and manufacturing companies in international groups.

 

Comments (0)

Add a Comment

This thread has been closed from taking new comments.